Fiche publication
Date publication
avril 2020
Journal
Cancers
Auteurs
Membres identifiés du Cancéropôle Est :
Dr AMARAL Teresa Maria
Tous les auteurs :
Amaral T, Seeber O, Mersi E, Sanchez S, Thomas I, Meiwes A, Forschner A, Leiter U, Eigentler T, Keim U, Garbe C
Lien Pubmed
Résumé
Primary resistance to immunotherapy can be observed in approximately 40-65% of the stage IV melanoma patients treated with immune checkpoint inhibitors. A minority of the patients receive a second-line therapy, and the clinical benefit is small.
Mots clés
checkpoint-inhibitors, combined immunotherapy, metastatic melanoma, primary resistance, pseudoprogression
Référence
Cancers (Basel). 2020 04 22;12(4):
